Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Operating Expenses (2016 - 2022)

Historic Operating Expenses for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to $7.7 million.

  • Aptevo Therapeutics' Operating Expenses fell 27.26% to $7.7 million in Q4 2022 from the same period last year, while for Sep 2023 it was $7.7 million, marking a year-over-year decrease of 7581.82%. This contributed to the annual value of $31.8 million for FY2022, which is 574.91% down from last year.
  • According to the latest figures from Q4 2022, Aptevo Therapeutics' Operating Expenses is $7.7 million, which was down 27.26% from $7.8 million recorded in Q3 2022.
  • In the past 5 years, Aptevo Therapeutics' Operating Expenses ranged from a high of $22.1 million in Q4 2019 and a low of $7.3 million during Q2 2020
  • In the last 5 years, Aptevo Therapeutics' Operating Expenses had a median value of $9.0 million in 2020 and averaged $11.1 million.
  • As far as peak fluctuations go, Aptevo Therapeutics' Operating Expenses plummeted by 5834.5% in 2020, and later skyrocketed by 2131.87% in 2021.
  • Quarter analysis of 5 years shows Aptevo Therapeutics' Operating Expenses stood at $15.5 million in 2018, then soared by 42.24% to $22.1 million in 2019, then crashed by 58.35% to $9.2 million in 2020, then fell by 16.18% to $7.7 million in 2021, then decreased by 0.27% to $7.7 million in 2022.
  • Its Operating Expenses was $7.7 million in Q4 2022, compared to $7.8 million in Q3 2022 and $7.6 million in Q2 2022.